Details of the Drug

General Information of Drug (ID: DMX38HQ)

Drug Name
Apomorphine
Synonyms Apomorphine (intranasal, Parkinson's disease)
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Approved [1], [2]
Idiopathic parkinson disease 8A00.0Z Phase 3 [3]
Sexual dysfunction HA00-HA01 Phase 2 [4]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 267.32
Topological Polar Surface Area (xlogp) 2.3
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 10-20 min [5]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [6]
Clearance
The clearance of drug is 1440 L/h [7]
Elimination
0.3% of drug is excreted from urine in the unchanged form [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.7 hours (15mg sublingual dose), and 50 minutes (intravenous dose) [7]
Metabolism
The drug is metabolized via the CYP2B6, 2C8, 3A4, and 3A5 [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.321 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.05% [9]
Vd
The volume of distribution (Vd) of drug is 123-404 L [7]
Water Solubility
The ability of drug to dissolve in water is measured as 20 mg/mL [6]
Chemical Identifiers
Formula
C17H17NO2
IUPAC Name
(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
Canonical SMILES
CN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O
InChI
InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1
InChIKey
VMWNQDUVQKEIOC-CYBMUJFWSA-N
Cross-matching ID
PubChem CID
6005
ChEBI ID
CHEBI:48538
CAS Number
58-00-4
DrugBank ID
DB00714
TTD ID
D0H6QU
VARIDT ID
DR00890
INTEDE ID
DR0123

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Agonist [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Sulfotransferase 1A1 (SULT1A1)
Main DME 		DEYWLRK ST1A1_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Parkinson disease
ICD Disease Classification 8A00.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
Sulfotransferase 1A1 (SULT1A1) DME SULT1A1 8.47E-01 3.57E-02 1.73E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Apomorphine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Pimavanserin. Parkinsonism [8A00] [32]
Coadministration of a Drug Treating the Disease Different from Apomorphine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Apomorphine and Ivosidenib. Acute myeloid leukaemia [2A60] [33]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Midostaurin. Acute myeloid leukaemia [2A60] [34]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Idarubicin. Acute myeloid leukaemia [2A60] [34]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Arn-509. Acute myeloid leukaemia [2A60] [35]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Gilteritinib. Acute myeloid leukaemia [2A60] [36]
Memantine DMD9WSC Minor Additive dopaminergic effects by the combination of Apomorphine and Memantine. Alzheimer disease [8A20] [35]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Apomorphine and Rivastigmine. Alzheimer disease [8A20] [34]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Apomorphine and Donepezil. Alzheimer disease [8A20] [34]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Apomorphine and Metronidazole. Amoebiasis [1A36] [37]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Apomorphine and Ivabradine. Angina pectoris [BA40] [35]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Apomorphine and Bepridil. Angina pectoris [BA40] [34]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Apomorphine and Dronedarone. Angina pectoris [BA40] [34]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Apomorphine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [38]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Cilostazol. Arterial occlusive disease [BD40] [34]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Posaconazole. Aspergillosis [1F20] [34]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Levalbuterol. Asthma [CA23] [39]
Terbutaline DMD4381 Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Terbutaline. Asthma [CA23] [40]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Apomorphine and Pirbuterol. Asthma [CA23] [40]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Apomorphine and Salbutamol. Asthma [CA23] [39]
Formoterol DMSOURV Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Formoterol. Asthma [CA23] [40]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [35]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Desipramine. Attention deficit hyperactivity disorder [6A05] [34]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Ofloxacin. Bacterial infection [1A00-1C4Z] [41]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Clarithromycin. Bacterial infection [1A00-1C4Z] [34]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Apomorphine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [34]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Apomorphine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [41]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [41]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Norfloxacin. Bacterial infection [1A00-1C4Z] [41]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Levofloxacin. Bacterial infection [1A00-1C4Z] [41]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [34]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Telithromycin. Bacterial infection [1A00-1C4Z] [34]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Loperamide. Bowel habit change [ME05] [42]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Eribulin. Breast cancer [2C60-2C6Y] [34]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Lapatinib. Breast cancer [2C60-2C6Y] [34]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Bosutinib. Breast cancer [2C60-2C6Y] [34]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Apomorphine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [43]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [40]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [39]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [40]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [40]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Apomorphine and Isoproterenol. Conduction disorder [BC63] [39]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Halothane. Corneal disease [9A76-9A78] [34]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Sevoflurane. Corneal disease [9A76-9A78] [34]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Probucol. Coronary atherosclerosis [BA80] [34]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Clofazimine. Crohn disease [DD70] [44]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Apomorphine and Mifepristone. Cushing syndrome [5A70] [34]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Apomorphine and Pasireotide. Cushing syndrome [5A70] [34]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Osilodrostat. Cushing syndrome [5A70] [35]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Apomorphine and Ethanol. Cystitis [GC00] [45]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Sertraline. Depression [6A70-6A7Z] [34]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Trimipramine. Depression [6A70-6A7Z] [34]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Apomorphine and Escitalopram. Depression [6A70-6A7Z] [34]
OPC-34712 DMHG57U Moderate Antagonize the effect of Apomorphine when combined with OPC-34712. Depression [6A70-6A7Z] [45]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Clomipramine. Depression [6A70-6A7Z] [34]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Doxepin. Depression [6A70-6A7Z] [34]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Maprotiline. Depression [6A70-6A7Z] [34]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [34]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Deutetrabenazine. Dystonic disorder [8A02] [46]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Apomorphine and Ingrezza. Dystonic disorder [8A02] [47]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Solifenacin. Functional bladder disorder [GC50] [34]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Pentamidine. Fungal infection [1F29-1F2F] [34]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Ketoconazole. Fungal infection [1F29-1F2F] [34]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [34]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [34]
Propiomazine DMKY8V1 Moderate Antagonize the effect of Apomorphine when combined with Propiomazine. Insomnia [7A00-7A0Z] [45]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Apomorphine and Polyethylene glycol. Irritable bowel syndrome [DD91] [35]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Apomorphine and Phenolphthalein. Irritable bowel syndrome [DD91] [34]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Apomorphine and Crizotinib. Lung cancer [2C25] [48]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Apomorphine and Ceritinib. Lung cancer [2C25] [34]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Apomorphine and Osimertinib. Lung cancer [2C25] [49]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Apomorphine and Selpercatinib. Lung cancer [2C25] [35]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Apomorphine and Lumefantrine. Malaria [1F40-1F45] [37]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Apomorphine and Halofantrine. Malaria [1F40-1F45] [50]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Apomorphine and Hydroxychloroquine. Malaria [1F40-1F45] [51]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Primaquine. Malaria [1F40-1F45] [34]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [35]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Apomorphine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [52]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Apomorphine and Vemurafenib. Melanoma [2C30] [34]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Apomorphine and LGX818. Melanoma [2C30] [53]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Apomorphine and Lasmiditan. Migraine [8A80] [54]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Apomorphine and Panobinostat. Multiple myeloma [2A83] [55]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Apomorphine and Thalidomide. Multiple myeloma [2A83] [56]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Apomorphine and Siponimod. Multiple sclerosis [8A40] [37]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Apomorphine and Fingolimod. Multiple sclerosis [8A40] [34]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Apomorphine and Ozanimod. Multiple sclerosis [8A40] [57]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Romidepsin. Mycosis fungoides [2B01] [34]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Apomorphine and Nilotinib. Myeloproliferative neoplasm [2A20] [34]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Dasatinib. Myeloproliferative neoplasm [2A20] [34]
Metoclopramide DMFA5MY Moderate Antagonize the effect of Apomorphine when combined with Metoclopramide. Nausea/vomiting [MD90] [45]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Entrectinib. Non-small cell lung cancer [2C25] [37]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Apomorphine and Levomethadyl Acetate. Opioid use disorder [6C43] [35]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Rucaparib. Ovarian cancer [2C73] [34]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Buprenorphine. Pain [MG30-MG3Z] [34]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Triclabendazole. Parasitic worm infestation [1F90] [34]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Famotidine. Peptic ulcer [DA61] [37]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Apomorphine and Macimorelin. Pituitary gland disorder [5A60-5A61] [58]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Apomorphine and Lefamulin. Pneumonia [CA40] [59]
Ritodrine DM4V6RL Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Ritodrine. Preterm labour/delivery [JB00] [40]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Degarelix. Prostate cancer [2C82] [35]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Apomorphine and ABIRATERONE. Prostate cancer [2C82] [35]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Enzalutamide. Prostate cancer [2C82] [35]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Bicalutamide. Prostate cancer [2C82] [35]
Levomepromazine DMIKFEL Moderate Antagonize the effect of Apomorphine when combined with Levomepromazine. Psychotic disorder [6A20-6A25] [45]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Apomorphine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [60]
Quetiapine DM1N62C Moderate Antagonize the effect of Apomorphine when combined with Quetiapine. Schizophrenia [6A20] [45]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Apomorphine and Mesoridazine. Schizophrenia [6A20] [34]
Aripiprazole DM3NUMH Moderate Antagonize the effect of Apomorphine when combined with Aripiprazole. Schizophrenia [6A20] [45]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Apomorphine and Iloperidone. Schizophrenia [6A20] [34]
Paliperidone DM7NPJS Moderate Antagonize the effect of Apomorphine when combined with Paliperidone. Schizophrenia [6A20] [45]
Perphenazine DMA4MRX Moderate Antagonize the effect of Apomorphine when combined with Perphenazine. Schizophrenia [6A20] [45]
Molindone DMAH70G Moderate Antagonize the effect of Apomorphine when combined with Molindone. Schizophrenia [6A20] [45]
Thiothixene DMDINC4 Moderate Antagonize the effect of Apomorphine when combined with Thiothixene. Schizophrenia [6A20] [45]
Risperidone DMN6DXL Moderate Antagonize the effect of Apomorphine when combined with Risperidone. Schizophrenia [6A20] [45]
Amisulpride DMSJVAM Major Antagonize the effect of Apomorphine when combined with Amisulpride. Schizophrenia [6A20] [37]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Asenapine. Schizophrenia [6A20] [34]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Apomorphine and Pimozide. Schizophrenia [6A20] [35]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Vardenafil. Sexual dysfunction [HA00-HA01] [34]
LEE011 DMMX75K Moderate Increased risk of prolong QT interval by the combination of Apomorphine and LEE011. Solid tumour/cancer [2A00-2F9Z] [34]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Apomorphine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [34]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [35]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [34]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [34]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Lenvatinib. Thyroid cancer [2D10] [34]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Apomorphine and Cabozantinib. Thyroid cancer [2D10] [35]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Apomorphine and Papaverine. Tonus and reflex abnormality [MB47] [61]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Tacrolimus. Transplant rejection [NE84] [34]
Methdilazine DMAUHQX Moderate Antagonize the effect of Apomorphine when combined with Methdilazine. Vasomotor/allergic rhinitis [CA08] [45]
Trimeprazine DMEMV9D Moderate Antagonize the effect of Apomorphine when combined with Trimeprazine. Vasomotor/allergic rhinitis [CA08] [45]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Apomorphine and Procainamide. Ventricular tachyarrhythmia [BC71] [34]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Propafenone. Ventricular tachyarrhythmia [BC71] [34]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Apomorphine and Flecainide. Ventricular tachyarrhythmia [BC71] [34]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Apomorphine and Amiodarone. Ventricular tachyarrhythmia [BC71] [34]
⏷ Show the Full List of 132 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 33).
2 ClinicalTrials.gov (NCT02339064) Infusion of Apomorphine: Long-term Safety Study. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Intranasal apomorphine. Nastech Pharmaceutical. IDrugs. 2004 May;7(5):483-8.
5 Jenner P, Katzenschlager R: Apomorphine - pharmacological properties and clinical trials in Parkinson's disease. Parkinsonism Relat Disord. 2016 Dec;33 Suppl 1:S13-S21. doi: 10.1016/j.parkreldis.2016.12.003. Epub 2016 Dec 13.
6 BDDCS applied to over 900 drugs
7 FDA Approved Drug Products: Apomorphine Subcutaneous Injection
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10 Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain--a comparative PET study with [11C]raclopride and [11C]MNPA. Synapse. 2009 May;63(5):378-89.
11 Sulfation of apomorphine by human sulfotransferases: evidence of a major role for the polymorphic phenol sulfotransferase, SULT1A1. Xenobiotica. 2003 Nov;33(11):1139-48.
12 Progestagenic effects of tibolone are target gene-specific in human endometrial cells. J Soc Gynecol Investig. 2006 Sep;13(6):459-65.
13 Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab Dispos. 2010 Jan;38(1):200-7.
14 Proposed role of the sulfotransferase/sulfatase pathway in modulating yolk steroid effects. Integr Comp Biol. 2008 Sep;48(3):419-27.
15 Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65.
16 Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
17 Natural products isolated from Mexican medicinal plants: novel inhibitors of sulfotransferases, SULT1A1 and SULT2A1. Phytomedicine. 2001 Nov;8(6):481-8.
18 Kinetic analysis of bile acid sulfation by stably expressed human sulfotransferase 2A1 (SULT2A1). Xenobiotica. 2010 Mar;40(3):184-94.
19 Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
20 Crystal structure of human sulfotransferase SULT1A3 in complex with dopamine and 3'-phosphoadenosine 5'-phosphate. Biochem Biophys Res Commun. 2005 Sep 23;335(2):417-23.
21 Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
22 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
23 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
24 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
25 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
26 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
27 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
28 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
29 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
30 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
31 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
32 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
33 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
34 Canadian Pharmacists Association.
35 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
36 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
37 Cerner Multum, Inc. "Australian Product Information.".
38 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
39 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
40 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
41 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
42 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
43 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
44 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
45 Product Information. Apokyn (apomorphine). Mylan Pharmaceuticals Inc, Morgantown, WV.
46 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
47 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
48 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
49 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
50 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
51 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
52 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
53 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
54 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
55 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
56 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
57 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
58 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
59 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
60 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
61 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]